Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PRC2 loss drives MPNST metastasis and matrix remodeling.

JCI insight - 24 Oct 2022

Brockman Qierra R, Scherer Amanda, McGivney Gavin R, Gutierrez Wade R, Voigt Andrew P, Isaacson Alexandra L, Laverty Emily A, Roughton Grace, Knepper-Adrian Vickie, Darbro Benjamin, Tanas Munir R, Stipp Christopher S, Dodd Rebecca D

Abstract excerpt

The histone methyltransferase PRC2 plays a complex role in cancer. Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas with frequent loss-of-function mutations in PRC2 that are associated with poor outcome. Here, we identify a critical role for PRC2 loss in driving MPNST metastasis. PRC2-dependent metastatic phenotypes included increased collagen-dependent invasion, upregulation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mice
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fibrosis

Share to Histone Methyltransferases

Source

Open in PubMed Open full text

Identifiers

PMID: 36066973
DOI: 10.1172/jci.insight.157502
PMCID: PMC9714789

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PRC2 loss drives MPNST metastasis and matrix remodeling.PMID 36066973Read ↗

A Sequencing Overview of Malignant Peripheral Nerve Sheath Tumors: Findings and Implications for TreatmentSemantic proximity Read ↗

PRC2 Restricts Malignant Peripheral Nerve Sheath Tumorigenesis in a Genetically Engineered Mouse Model of MPNSTSemantic proximity Read ↗

Integrated Proteomic and Epigenomic Analysis Reveals IGF2 as a Vulnerability in PRC2-Deficient Malignant Peripheral Nerve Sheath TumorsSemantic proximity Read ↗

Identification of Malignant Peripheral Nerve Sheath Tumor subtypes with distinct genomic identitiesSemantic proximity Read ↗

Cross-species Study of Canine and Human Peripheral Nerve Sheath Tumors: Clinical and Molecular PerspectivesSemantic proximity Read ↗

From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor.Semantic proximity Read ↗

The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.Semantic proximity Read ↗

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.Semantic proximity Read ↗

Epigenomic Reordering Induced by Polycomb Loss Drives Oncogenesis but Leads to Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath TumorsSemantic proximity Read ↗

The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumorsSemantic proximity Read ↗

Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilitiesSemantic proximity Read ↗

Genomic patterns of malignant peripheral nerve sheath tumour (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.